Clinical Trials Browser

Phase 3 × pembrolizumab × Head & Neck × Clear all

NCT06589804 2026-03-18

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT05523323 2026-03-13

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension

Phase 3 Completed

112 enrolled 16 charts

Squamous Cell Carcinoma of Head and Neck

NCT07276399 2026-03-13

OrigAMI-5

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT04222972 2026-03-05

AcceleRET-Lung

Phase 3 Terminated

223 enrolled 18 charts

Head & NeckThoracic

Adenocarcinoma, Bronchial Diseases, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT05721755 2026-03-05

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 3 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT07026474 2026-03-02

RePaIr-HN

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06525220 2026-02-23

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Laryngeal Diseases

NCT03040999 2026-02-04

KEYNOTE-412

Phase 3 Completed

804 enrolled 20 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05815927 2026-02-02

PROLoNg

Phase 3 Recruiting

Oligometastatic Squamous Cell Carcinoma of the Head and Neck

NCT06998069 2025-12-30

Head and Neck Cancer Study Project in the Geriatric Population

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Phase 3 Completed

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT07264075 2025-12-04

ILLUMINE

Phase 3 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03358472 2025-12-03

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Phase 3 Completed

89 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06699212 2025-10-15

ECLIPSE

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT03765918 2025-08-20

MK-3475-689

Phase 3 Active not recruiting

714 enrolled 90 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Head and Neck Neoplasms

NCT02358031 2025-07-18

MK-3475-048

Phase 3 Completed

882 enrolled 50 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Head and Neck Neoplasms

NCT04199104 2025-04-23

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

Phase 3 Completed

511 enrolled 20 charts

Squamous Cell Carcinoma of Head and Neck

NCT04747054 2024-10-26

PembroMetaRT

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Squamous Cell, Neoplasm Metastasis

NCT04428333 2024-10-09

INDUCE-4

Phase 3 Terminated

117 enrolled 33 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04128696 2024-07-10

INDUCE-3

Phase 3 Terminated

315 enrolled 31 charts

Head and Neck Neoplasms, Neoplasms

NCT06102395 2023-10-30

Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT02611960 2023-07-13

Keynote-122

Phase 3 Completed

233 enrolled 21 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Nasopharyngeal Neoplasms